196 related articles for article (PubMed ID: 28943357)
21. JNK phosphorylation relieves HDAC3-dependent suppression of the transcriptional activity of c-Jun.
Weiss C; Schneider S; Wagner EF; Zhang X; Seto E; Bohmann D
EMBO J; 2003 Jul; 22(14):3686-95. PubMed ID: 12853483
[TBL] [Abstract][Full Text] [Related]
22. Formation of AR-SMRT binding in prostate cancer cells treated with natural histone deacetylase inhibitor.
Trtková K; Pašková L; Matiješčuková N; Kolář Z
Cancer Biomark; 2010; 7(2):79-90. PubMed ID: 21178266
[TBL] [Abstract][Full Text] [Related]
23. Synthesis and biological evaluation of histone deacetylase and DNA topoisomerase II-Targeted inhibitors.
Yamashita M; Tahara T; Hayakawa S; Matsumoto H; Wada SI; Tomioka K; Iida A
Bioorg Med Chem; 2018 May; 26(8):1920-1928. PubMed ID: 29519604
[TBL] [Abstract][Full Text] [Related]
24. Novel N-hydroxyfurylacrylamide-based histone deacetylase (HDAC) inhibitors with branched CAP group (Part 2).
Feng T; Wang H; Su H; Lu H; Yu L; Zhang X; Sun H; You Q
Bioorg Med Chem; 2013 Sep; 21(17):5339-54. PubMed ID: 23820574
[TBL] [Abstract][Full Text] [Related]
25. Design and synthesis of novel and highly-active pan-histone deacetylase (pan-HDAC) inhibitors.
Tashima T; Murata H; Kodama H
Bioorg Med Chem; 2014 Jul; 22(14):3720-31. PubMed ID: 24864038
[TBL] [Abstract][Full Text] [Related]
26. Molecular basis for the antiparasitic activity of a mercaptoacetamide derivative that inhibits histone deacetylase 8 (HDAC8) from the human pathogen schistosoma mansoni.
Stolfa DA; Marek M; Lancelot J; Hauser AT; Walter A; Leproult E; Melesina J; Rumpf T; Wurtz JM; Cavarelli J; Sippl W; Pierce RJ; Romier C; Jung M
J Mol Biol; 2014 Oct; 426(20):3442-53. PubMed ID: 24657767
[TBL] [Abstract][Full Text] [Related]
27. Colon cancer cells maintain low levels of pyruvate to avoid cell death caused by inhibition of HDAC1/HDAC3.
Thangaraju M; Carswell KN; Prasad PD; Ganapathy V
Biochem J; 2009 Jan; 417(1):379-89. PubMed ID: 18789002
[TBL] [Abstract][Full Text] [Related]
28. A novel histone deacetylase pathway regulates mitosis by modulating Aurora B kinase activity.
Li Y; Kao GD; Garcia BA; Shabanowitz J; Hunt DF; Qin J; Phelan C; Lazar MA
Genes Dev; 2006 Sep; 20(18):2566-79. PubMed ID: 16980585
[TBL] [Abstract][Full Text] [Related]
29. Towards selective inhibition of histone deacetylase isoforms: what has been achieved, where we are and what will be next.
Thaler F; Mercurio C
ChemMedChem; 2014 Mar; 9(3):523-6. PubMed ID: 24730063
[TBL] [Abstract][Full Text] [Related]
30. Potent and Selective Inhibitors of Histone Deacetylase-3 Containing Chiral Oxazoline Capping Groups and a N-(2-Aminophenyl)-benzamide Binding Unit.
Marson CM; Matthews CJ; Atkinson SJ; Lamadema N; Thomas NS
J Med Chem; 2015 Sep; 58(17):6803-18. PubMed ID: 26287310
[TBL] [Abstract][Full Text] [Related]
31. Docking of hydroxamic acids into HDAC1 and HDAC8: a rationalization of activity trends and selectivities.
Ortore G; Di Colo F; Martinelli A
J Chem Inf Model; 2009 Dec; 49(12):2774-85. PubMed ID: 19947584
[TBL] [Abstract][Full Text] [Related]
32. SAHA Capture Compound--a novel tool for the profiling of histone deacetylases and the identification of additional vorinostat binders.
Fischer JJ; Michaelis S; Schrey AK; Diehl A; Graebner OY; Ungewiss J; Horzowski S; Glinski M; Kroll F; Dreger M; Koester H
Proteomics; 2011 Oct; 11(20):4096-104. PubMed ID: 21898820
[TBL] [Abstract][Full Text] [Related]
33. Troglitazone inhibits histone deacetylase activity in breast cancer cells.
Davies GF; Ross AR; Arnason TG; Juurlink BH; Harkness TA
Cancer Lett; 2010 Feb; 288(2):236-50. PubMed ID: 19699029
[TBL] [Abstract][Full Text] [Related]
34. Benzofused hydroxamic acids: useful fragments for the preparation of histone deacetylase inhibitors. Part 1: hit identification.
Marastoni E; Bartoli S; Berettoni M; Cipollone A; Ettorre A; Fincham CI; Mauro S; Paris M; Porcelloni M; Bigioni M; Binaschi M; Nardelli F; Parlani M; Maggi CA; Fattori D
Bioorg Med Chem Lett; 2013 Jul; 23(14):4091-5. PubMed ID: 23768910
[TBL] [Abstract][Full Text] [Related]
35. Blockade of histone deacetylase inhibitor-induced RelA/p65 acetylation and NF-kappaB activation potentiates apoptosis in leukemia cells through a process mediated by oxidative damage, XIAP downregulation, and c-Jun N-terminal kinase 1 activation.
Dai Y; Rahmani M; Dent P; Grant S
Mol Cell Biol; 2005 Jul; 25(13):5429-44. PubMed ID: 15964800
[TBL] [Abstract][Full Text] [Related]
36. Histone deacetylase 3 inhibitors in learning and memory processes with special emphasis on benzamides.
Amin SA; Adhikari N; Kotagiri S; Jha T; Ghosh B
Eur J Med Chem; 2019 Mar; 166():369-380. PubMed ID: 30735902
[TBL] [Abstract][Full Text] [Related]
37. Alkyl piperidine and piperazine hydroxamic acids as HDAC inhibitors.
Rossi C; Porcelloni M; D'Andrea P; Fincham CI; Ettorre A; Mauro S; Squarcia A; Bigioni M; Parlani M; Nardelli F; Binaschi M; Maggi CA; Fattori D
Bioorg Med Chem Lett; 2011 Apr; 21(8):2305-8. PubMed ID: 21420859
[TBL] [Abstract][Full Text] [Related]
38. Carbamate prodrug concept for hydroxamate HDAC inhibitors.
Schlimme S; Hauser AT; Carafa V; Heinke R; Kannan S; Stolfa DA; Cellamare S; Carotti A; Altucci L; Jung M; Sippl W
ChemMedChem; 2011 Jul; 6(7):1193-8. PubMed ID: 21416613
[No Abstract] [Full Text] [Related]
39. Determination of the class and isoform selectivity of small-molecule histone deacetylase inhibitors.
Khan N; Jeffers M; Kumar S; Hackett C; Boldog F; Khramtsov N; Qian X; Mills E; Berghs SC; Carey N; Finn PW; Collins LS; Tumber A; Ritchie JW; Jensen PB; Lichenstein HS; Sehested M
Biochem J; 2008 Jan; 409(2):581-9. PubMed ID: 17868033
[TBL] [Abstract][Full Text] [Related]
40. Expression patterns of histone deacetylases in experimental stroke and potential targets for neuroprotection.
Chen YT; Zang XF; Pan J; Zhu XL; Chen F; Chen ZB; Xu Y
Clin Exp Pharmacol Physiol; 2012 Sep; 39(9):751-8. PubMed ID: 22651689
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
